Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations in women undergoing in vitro fertilization.

Vascular endothelial growth factor (VEGF) is a powerful mediator for vessel permeability and it is strongly implicated in angiogenesis, stimulating endothelial cell proliferation as well as capillary permeability. We studied 30 women undergoing in vitro fertilization (IVF) programs and evaluated, on the day of oocyte retrieval, VEGF levels in plasma and follicular fluid and related such concentrations to the amount of follicle-stimulating hormone (FSH) administered. Furthermore, the correlation between the number of oocytes retrieved and the VEGF concentrations both in plasma and in follicular fluid were also investigated. Results indicate that follicular fluid VEGF concentrations and the amount of pure FSH administered were directly proportional (p < 0.05). On the day of oocyte retrieval, the VEGF plasma concentrations and the number of oocytes collected were directly proportional (p < 0.05). VEGF plasma levels increased after human chorionic gonadotropin (hCG) administration (30.37 +/- 18.60 pg/ml up to 52.62 +/- 43.63 pg/ml). In conclusion, this study demonstrates that the doses of pure FSH administered to women undergoing IVF cycles have a crucial role in hCG-dependent VEGF production.

[1]  R. Stouffer,et al.  Vascular endothelial growth factor production by human luteinized granulosa cells in vitro. , 1997, Human reproduction.

[2]  D. Seifer,et al.  Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. , 1997, Fertility and sterility.

[3]  A. Ferrari,et al.  Expression of vascular endothelial growth factor in human luteinizing granulosa cells and its correlation with the response to controlled ovarian hyperstimulation. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  R. Stouffer,et al.  Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. , 1997, Fertility and sterility.

[5]  R. Stouffer,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Follicle-Stimulating Hormone and Luteinizing Hormone/ Chorionic Gonadotropin Stimulation of Vascular Endothelial Growth Factor Production by Macaq , 2022 .

[6]  S. Berga,et al.  Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. , 1996, Fertility and sterility.

[7]  R. Edwards,et al.  Principles and Practice of Assisted Human Reproduction , 1995 .

[8]  M. Breckwoldt,et al.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. , 1995, The Journal of clinical endocrinology and metabolism.

[9]  D. Connolly,et al.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome , 1994, The Lancet.

[10]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[11]  M. Breckwoldt,et al.  Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. , 1993, The Journal of clinical endocrinology and metabolism.

[12]  D. Charnock-Jones,et al.  Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. , 1993, Biology of reproduction.

[13]  N. Ferrara,et al.  Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.

[14]  I. Carlson,et al.  Diagnosis-specific serum 17 beta-estradiol (E2) upper limits for treatment with menotropins using a 125I direct E2 assay. , 1984, Fertility and sterility.

[15]  P. Fishman,et al.  Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. , 1995, Human reproduction.

[16]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. , 1995, American Journal of Pathology.

[17]  H. Dvorak,et al.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. , 1991, The American journal of pathology.